Zobrazeno 1 - 10
of 180
pro vyhledávání: '"Jean D. Boyer"'
Autor:
Elizabeth M. Parzych, Jianqiu Du, Ali R. Ali, Katherine Schultheis, Drew Frase, Trevor R. F. Smith, Jiayan Cui, Neethu Chokkalingam, Nicholas J. Tursi, Viviane M. Andrade, Bryce M. Warner, Ebony N. Gary, Yue Li, Jihae Choi, Jillian Eisenhauer, Igor Maricic, Abhijeet Kulkarni, Jacqueline D. Chu, Gabrielle Villafana, Kim Rosenthal, Kuishu Ren, Joseph R. Francica, Sarah K. Wootton, Pablo Tebas, Darwyn Kobasa, Kate E. Broderick, Jean D. Boyer, Mark T. Esser, Jesper Pallesen, Dan W. Kulp, Ami Patel, David B. Weiner
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Here, Parzych et al describe the development of a DNA-delivered SARS-CoV-2 mAb cocktail displaying synergistic RBD binding that confers broad neutralizing activity against variants of concern and prophylactic efficacy in multiple small animal models.
Externí odkaz:
https://doaj.org/article/dec1ebc23ee2448fb7ad32d2457e1b56
Autor:
Viviane M. Andrade, Aaron Christensen-Quick, Joseph Agnes, Jared Tur, Charles Reed, Richa Kalia, Idania Marrero, Dustin Elwood, Katherine Schultheis, Mansi Purwar, Emma Reuschel, Trevor McMullan, Patrick Pezzoli, Kim Kraynyak, Albert Sylvester, Mammen P. Mammen, Pablo Tebas, J. Joseph Kim, David B. Weiner, Trevor R. F. Smith, Stephanie J. Ramos, Laurent M. Humeau, Jean D. Boyer, Kate E. Broderick
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-4 (2021)
Abstract Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to vaccine-induced immunity. Here we compared humoral and cellular responses again
Externí odkaz:
https://doaj.org/article/861f6b3de24f4eca965d9adae892bcdd
Autor:
Pablo Tebas, ShuPing Yang, Jean D. Boyer, Emma L. Reuschel, Ami Patel, Aaron Christensen-Quick, Viviane M. Andrade, Matthew P. Morrow, Kimberly Kraynyak, Joseph Agnes, Mansi Purwar, Albert Sylvester, Jan Pawlicki, Elisabeth Gillespie, Igor Maricic, Faraz I. Zaidi, Kevin Y. Kim, Yaya Dia, Drew Frase, Patrick Pezzoli, Katherine Schultheis, Trevor R.F. Smith, Stephanie J. Ramos, Trevor McMullan, Karen Buttigieg, Miles W. Carroll, John Ervin, Malissa C. Diehl, Elliott Blackwood, Mammen P. Mammen, Jessica Lee, Michael J. Dallas, Ami Shah Brown, Jacqueline E. Shea, J.Joseph Kim, David B. Weiner, Kate E. Broderick, Laurent M. Humeau
Publikováno v:
EClinicalMedicine, Vol 31, Iss , Pp 100689- (2021)
Background: A vaccine against SARS-CoV-2 is of high urgency. Here the safety and immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of SARS-CoV-2 are described. Methods: INO-4800 was evaluated in two groups of
Externí odkaz:
https://doaj.org/article/a9f1cb97a12243469984e15dede48ebe
Autor:
Srilatha Edupuganti, Stephen C. De Rosa, Marnie Elizaga, Yiwen Lu, Xue Han, Yunda Huang, Edith Swann, Laura Polakowski, Spyros A. Kalams, Michael Keefer, Janine Maenza, Megan C. Wise, Jian Yan, Matthew P. Morrow, Amir S. Khan, Jean D. Boyer, Laurent Humeau, Scott White, Niranjan Y. Sardesai, Mark L. Bagarazzi, Peter B. Gilbert, James G. Kublin, Lawrence Corey, David B. Weiner, on behalf of the HVTN 098 Study Team, the NIAID-Funded HIV Vaccine Trials Network
Publikováno v:
Vaccines, Vol 8, Iss 4, p 741 (2020)
Background: Several techniques are under investigation to improve the immunogenicity of HIV-1 DNA vaccine candidates. DNA vaccines are advantageous due to their ease of design, expression of multiple antigens, and safety. Methods: The HVTN 098 trial
Externí odkaz:
https://doaj.org/article/c5714f0380a34333bb5f95d0bc5749e7
Autor:
Mark L. Bagarazzi, Cornelia L. Trimble, David B. Weiner, Stanley Plotkin, J. Joseph Kim, Niranjan Y. Sardesai, Laurent Humeau, Amir S. Khan, Russell Vang, Jian Yan, Jean D. Boyer, Dawson Knoblock, Michael Dallas, Albert J. Sylvester, Kimberly A. Kraynyak, Matthew P. Morrow
Supplemental Figure 1 - Rates of CIN2/3 regression (primary endpoint) or CIN2/3 regression concomitant with clearance of HPV16 and/or HPV18 infection (secondary endpoint) in the Per Protocol population of the Phase IIb study of VGX-3100 for the treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aba4a17eb58c63a1341c4b673bd3881
https://doi.org/10.1158/1078-0432.22467135.v1
https://doi.org/10.1158/1078-0432.22467135.v1
Autor:
Mark L. Bagarazzi, Cornelia L. Trimble, David B. Weiner, Stanley Plotkin, J. Joseph Kim, Niranjan Y. Sardesai, Laurent Humeau, Amir S. Khan, Russell Vang, Jian Yan, Jean D. Boyer, Dawson Knoblock, Michael Dallas, Albert J. Sylvester, Kimberly A. Kraynyak, Matthew P. Morrow
Purpose: As previously reported, treatment of high-grade cervical dysplasia with VGX-3100 resulted in complete histopathologic regression (CR) concomitant with elimination of HPV16/18 infection in 40.0% of VGX-3100–treated patients compared with on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b28af5e03ba2006f897889071c16ba8
https://doi.org/10.1158/1078-0432.c.6526548.v1
https://doi.org/10.1158/1078-0432.c.6526548.v1
Autor:
Mark L. Bagarazzi, Cornelia L. Trimble, David B. Weiner, Stanley Plotkin, J. Joseph Kim, Niranjan Y. Sardesai, Laurent Humeau, Amir S. Khan, Russell Vang, Jian Yan, Jean D. Boyer, Dawson Knoblock, Michael Dallas, Albert J. Sylvester, Kimberly A. Kraynyak, Matthew P. Morrow
Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781222e7481bb332437ebd226d7503f2
https://doi.org/10.1158/1078-0432.22467138
https://doi.org/10.1158/1078-0432.22467138
Autor:
Subeena Sood, Jean D. Boyer, Jessica Kim, Majed M. Matar, Olivia Signer, Jennifer S. Rice, Alanna M. Smith, Nicholas Borys, Khursheed Anwer
Publikováno v:
Cancer Research. 83:4440-4440
Introduction: The purpose of this study was to investigate the effect of dosing frequency on the antitumor activity of intraperitoneal GEN-1, an interleukin-12 (IL-12) immune gene therapy in a mouse model of peritoneally disseminated ovarian cancer.
Autor:
Joseph L. Kim, Jean D. Boyer, Susan Duff, Michael J. Dallas, Kim Kraynyak, Prakash K. Bhuyan, Timothy A. Herring, Matthew P. Morrow, David B. Weiner
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
VGX-3100 is an investigational DNA-based immunotherapy being developed as an alternative to surgery and ablation for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) with the aim of preserving reproductive health while treating precancerous
Autor:
Larissa V. Furtado, Anne R. McCall, Matthew P. Morrow, Gini F. Fleming, Rakesh Kumar, Fauzia Arif, Mark T. Esser, Yasmin Hasan, David L. Schwartz, Jeffrey M. Skolnik, Kimberly A. Kraynyak, Rebecca A. Brooks, Jean D. Boyer, Daniel W. Golden, Shruti Jolly, Matt Levin, Ana I. Tergas, Nita Lee, Michael T. Spiotto, Ralph R. Weichselbaum, Mark L. Bagarazzi, Albert Sylvester
Publikováno v:
Int J Radiat Oncol Biol Phys
PURPOSE: This study assessed the safety and tolerability of therapeutic immunization against the human papillomavirus (HPV) viral oncoproteins E6 and E7 in patients with cervical cancer after chemoradiation. METHODS AND MATERIALS: MEDI0457 (INO-3112)